Lung Cancer News

An FDA advisory committee today voted 6-5 in favor of recommending approval of ramucirumab injection in combination with erlotinib for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations.

The FDA granted priority review to brigatinib as first-line treatment for anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, according to the agent’s manufacturer.

The FDA granted priority review to atezolizumab monotherapy as first-line treatment for patients with advanced nonsquamous or squamous non-small cell lung cancer without EGFR or ALK mutations and with high PD-L1 expression, according to a press release from the agent’s manufacturer.

A multi-disciplinary task force issued guidance for vaping-associated respiratory disease, or VARDS. The nationwide guidance, which was presented at the Society for Critical Care’s annual congress and concurrently published in Critical Care Explorations, recommended that physicians focusing on quickly identifying patients at risk for lung injury and familiarize themselves with vaping jargon.

The FDA granted priority review to lurbinectedin for the treatment of small cell lung cancer that relapsed after platinum-based therapy, according to a press release from the agent’s manufacturer.

In a study of models for predicting malignancy in pulmonary nodules, researchers found that those developed using data from the Pan-Canadian Early Detection of Lung Cancer low-dose CT screening trial showed good discrimination and fared better than several other prediction models.

The FDA granted priority review to capmatinib for the treatment of patients with advanced non-small cell lung cancer who harbor MET exon 14 skipping mutations.

Pembrolizumab induced encouraging antitumor activity among a cohort of patients with recurrent or metastatic small cell lung cancer, according to a pooled analysis of data from the KEYNOTE-028 and KEYNOTE-158 studies published in Journal of Thoracic Oncology.

A video patient decision aid delivered to tobacco quit line clients led to more informed decision making about lung cancer screening, according to data published in JAMA Network Open.

The addition of dinutuximab to irinotecan failed to extend OS among patients with relapsed or refractory small cell lung cancer, according to topline data from a randomized phase 2/phase 3 trial released by the agent’s manufacturer.